In this session, Dr. Neil Thakur and Dr. Kuldip Dave from The ALS Association talk about the implications of additional results from the Open Label Study of the CENTAUR trial for the ALS community. They discuss The ALS Association's plans for helping the ALS community influence when AMX0035 might be approved for clinical use.
The views and opinions expressed in this webinar do not necessarily reflect the position of NEALS, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, or Amylyx.
